Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration

Ophthalmic Research

Volumn 38, Issue 6, 2006, Pages 324-328

  Jonas, Jost B ^a,b   Spandau, Ulrich H ^a   Kamppeter, Bernd A ^a   Vossmerbaeumer, Urs ^a   Harder, Bjoern ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Age related macular degeneration; Intraocular neovascularization; Intravitreal steroids; Intravitreal triamcinolone acetonide; Macular disease

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REPEAT PROCEDURE; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL SIGNIFICANCE; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 33750716108     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096226     Document Type: Article

References (36)

1. Folkman J, Ingber DE: Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987;206:374-383.
2. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-711.
3. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL: The effects of intravitreal triamcinolone acetonide on experimental preretinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
4. Danis RP, Bingaman DP, Yang Y, Ladd B: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104.
5. Penfold PL, Gyory JF, Hunyor AB, Billson FA: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol 1995;23:293-298.
6. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA: Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-281.
7. Penfold PL: Intravitreal triamcinolone in recurrence of choroidal neovascularization. Br J Ophthalmol 2002;86:600-601.
8. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
9. Ranson NT, Danis RP, Ciulla TA, Pratt L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-529.
10. Jonas JB, Kreissig I, Degenring RF: Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:873-874.
11. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R: Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003;87:462-468.
12. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF: Intravitreal re-injection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-222.
13. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I: Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative non-randomized study. Eye 2005;19:163-170.
14. Jonas JB, Kreissig I, Degenring RF: Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration. Br J Ophthalmol 2004;88:1557-1562.
15. Jonas JB, Spandau UH, Harder B, Vossmerbaeumer U, Kamppeter BA: Inter-eye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2005;139:1073-1079.
16. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-673.
17. Jonas JB, Kreissig I, Degenring RF: Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-1664.
18. Spandau UHM, Derse M, Schmitz-Valckenberg P, Papoulis C, Sagstetter BU, Stiefvater KH, Jonas JB: Measurement of triamcinolone acetonide concentration after filtering of solvent agent. Am J Ophthalmol 2005;139:712-713.
19. Vingerling JR, Dielemans I, Hofman A, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205-210.
20. Mitchell P, Smith W, Attebo K, Wang JJ: Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-1460.
21. Congdon N, O'Connor B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group: Causes and prevalences of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485.
22. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207.
23. Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560.
24. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report No. 5. Arch Ophthalmol 2002;120:1307-1314.
25. Kaiser PK: Verteprofin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Curr Med Res Opin 2005;5:705-706.
26. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U: Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748-757.
27. Jonas JB, Kreissig I, Degenring RF: Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:872-873.
28. Spaide RF, Sorenson J, Maranan L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
29. Spaide RF, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304
30. Smithen LM, Spaide RF: Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004;138:884-885.
31. Rechtman E, Danis RP, Pratt LM, Harris A: Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 2004;88:344-347.
32. Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
33. Augustin AJ, Schmidt-Erfurth U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularisation in age-related macular degeneration. Am J Ophthalmol 2006;141:638-645.
34. Arevalo JF, Garcia RA, Mendoza AJ: Indocyanine green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005;243:1180-1185.
35. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:642e1-4.
36. Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.